Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

BACKGROUND: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAF(V600E) and MET amplification. However after 4 months, acquired resistance emerged and the patient deceased shortly after disease progression. The mechanism of resistance to this drug co...

Descripción completa

Detalles Bibliográficos
Autores principales: Oddo, Daniele, Siravegna, Giulia, Gloghini, Annunziata, Vernieri, Claudio, Mussolin, Benedetta, Morano, Federica, Crisafulli, Giovanni, Berenato, Rosa, Corti, Giorgio, Volpi, Chiara Costanza, Buscarino, Michela, Niger, Monica, Dunne, Philip D, Rospo, Giuseppe, Valtorta, Emanuele, Bartolini, Alice, Fucà, Giovanni, Lamba, Simona, Martinetti, Antonia, Di Bartolomeo, Maria, de Braud, Filippo, Bardelli, Alberto, Pietrantonio, Filippo, Di Nicolantonio, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537500/
https://www.ncbi.nlm.nih.gov/pubmed/28654634
http://dx.doi.org/10.1038/bjc.2017.196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537500/
https://www.ncbi.nlm.nih.gov/pubmed/28654634
http://dx.doi.org/10.1038/bjc.2017.196

Ejemplares similares